Can-Fite BioPharma presented final positive data from its Phase IIa clinical study of namodenoson in advanced pancreatic ductal adenocarcinoma at the ESMO 2026 Congress. The single-center, open-label trial enrolled 20 patients and achieved its primary safety endpoint, demonstrating that oral namodenoson was well tolerated with only mild to moderate adverse events and no Grade ≥3 treatment-related events. Exploratory analyses highlighted encouraging survival outcomes in heavily pretreated patients, including a median overall survival of 6.28 months for third-line survivors beyond two months. One second-line patient achieved progression-free survival of 16.39 months and overall survival exceeding 20.7 months. These hypothesis-generating findings support further clinical development of the drug in this challenging disease. Can-Fite BioPharma is a biotechnology company developing small molecule therapeutics targeting cancer, liver, and inflammatory diseases.
